Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioCardia, Inc. (NASDAQ: BCDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease, BioCardia uses these filings to report on financial results, governance matters, clinical and regulatory milestones, and capital markets activity.
Here you can review current reports on Form 8-K, which BioCardia uses to announce material events such as quarterly financial results, progress in its CardiAMP and CardiALLO clinical programs, enrollment updates in the CardiAMP HF II Phase 3 trial, consultations with Japan’s PMDA, leadership and board changes, and notices related to Nasdaq listing compliance. These filings often incorporate or reference press releases that detail developments in the company’s investigational therapies and enabling technologies like the Helix delivery system and Morph vascular navigation platform.
Investors can also consult proxy materials such as the definitive proxy statement on Schedule DEF 14A, which outlines proposals for director elections, amendments to the equity incentive plan, auditor ratification, and advisory votes on executive compensation, as well as information on board structure and corporate governance. Periodic reports on Forms 10-K and 10-Q, referenced in company communications, provide broader context on risk factors, financial condition, and the status of clinical programs.
Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand the significance of lengthy filings, including complex sections on clinical trial status, equity financings, and listing compliance. Real-time updates from EDGAR, along with structured access to items such as results of operations, other events, and shareholder meeting notices, make this BCDA filings page a focused resource for analyzing BioCardia’s regulatory and corporate disclosures.
BioCardia, Inc. director receives new stock option grant. A company director reported receiving a stock option to buy 12,000 shares of BioCardia common stock at an exercise price of
According to the filing, all of the shares under this option vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date. After this grant, the reporting person beneficially owns 15,573 derivative securities (stock options) on a direct basis, with the reported option expiring on
BioCardia, Inc. reported an insider equity award for one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option is classified as a derivative security because it represents the right to buy common stock in the future at a fixed price.
All 12,000 option shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues to serve as a service provider through that date. The option expires on 12/08/2035 if not exercised earlier. After this grant, the director beneficially owns 12,000 derivative securities directly in the form of this stock option.
BioCardia, Inc. filed an initial ownership report showing no securities held by the reporting director. A Form 3 was filed for an individual who serves as a director of BioCardia, Inc. (ticker BCDA) for an event dated 12/02/2025. The filing indicates that the form is filed by one reporting person and includes a remark stating that no securities are beneficially owned. An Exhibit 24 power of attorney is referenced, authorizing the signatory to sign on behalf of the reporting person.
BioCardia, Inc. (BCDA) reported an organizational update. The company announced in an 8-K that, on November 24, 2025, it issued a press release appointing Farhan Shahab as Vice President of Quality. This role typically oversees and supports quality systems and compliance for products and operations, which is important for companies operating in regulated medical and life science markets.
The press release describing the appointment is included as Exhibit 99.1, and the company notes that this information is being furnished, not filed, under securities laws, meaning it is provided for disclosure purposes without triggering certain liability provisions.
BioCardia, Inc. filed a current report to furnish its latest quarterly results update. On November 12, 2025, the company issued a press release announcing its financial results for the quarter ended September 30, 2025, and attached that release as an exhibit.
The press release is provided as Exhibit 99.1 and is treated as "furnished" rather than "filed" under securities law, which limits certain legal liabilities and incorporation by reference into other SEC documents unless specifically cited.
BioCardia (BCDA) reported an operational milestone: it announced the first patient enrolled at Henry Ford Health in its ongoing Phase 3 CardiAMP HF II clinical trial for patients with “ischemia heart failure of reduced ejection fraction.”
The announcement was made via a press release furnished as Exhibit 99.1. The information is being furnished under Item 8.01 and is not deemed filed under the Exchange Act.
BioCardia (BCDA) scheduled its 2025 annual meeting for 9:00 a.m. PT on December 2, 2025 at Wilson Sonsini in Palo Alto. Stockholders of record as of October 8, 2025 may vote; there were 10,612,734 shares outstanding on the record date.
Stockholders will vote on: (1) the election of three Class III directors; (2) an amended and restated 2016 Equity Incentive Plan to extend the plan to October 31, 2035, change the “evergreen” to 4.0% of outstanding shares added on the meeting date and each fiscal year start, and limit incentive stock option capacity; and (3) ratification of PKF San Diego, LLP as auditor for 2025. The filing also includes a non-binding advisory vote on executive compensation.
Based on shares outstanding on the record date, the initial increase upon approval would be 424,509 shares. As of November 3, 2025, approximately 95,000 shares remained available under the current plan. Audit fees to PKF were $278,000 in 2024 and $261,000 in 2023. Internet/telephone voting closes at 11:59 p.m. ET on December 1, 2025.
BioCardia (BCDA) announced the first patient was enrolled at the University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial. The update was disclosed under Item 8.01 as a furnished report, and a press release is included as Exhibit 99.1 dated October 30, 2025. The information is furnished, not filed, under the Exchange Act.
BioCardia, Inc. filed an amended Q2 2025 10‑Q solely to add the CEO/CFO certifications omitted from the original filing; no other changes were made.
For the quarter ended June 30, 2025, the company reported a net loss of
Research and development expense was
BCDA filed a prospectus supplement updating its at‑the‑market offering program for common stock through H.C. Wainwright & Co. The supplement sets a new maximum aggregate amount of $5,309,253 that may be sold under the program, after effectiveness and subject to offering conditions.
The company notes it has previously received approximately $3.9 million of gross proceeds from sales under the same program. Eligibility is based on an aggregate market value of non‑affiliate shares of approximately $20.1 million, calculated using 8,846,053 non‑affiliate shares at a $2.27 per‑share price as of September 11, 2025, and is constrained by Form S‑3 General Instruction I.B.6 (one‑third cap). During the 12‑month period ending on the date hereof, the company sold approximately $1.4 million pursuant to I.B.6.